HCA Redflag - Novo Nordisk (AI)
Summary
- Novo Nordisk has raised its 2026 guidance for adjusted revenue and operating growth to 0% to -6% at CER, driven by higher GLP-1 expectations, and increased its FCF guidance to DKK 45-55 billion.
- The oral Wegovy pill achieved a historic launch with over 5 million prescriptions and significant growth in obesity care, now launched in the UAE and UK, and EU-approved in July.
- Despite strong cash flow and capital distribution, reported EBIT fell 16% and net income 21% in Q2, impacted by a DKK 6.3 billion markdown on the pipeline and a decrease in gross margin.
- Significant price reductions for Wegovy and Ozempic are expected in 2027, and pipeline disappointments, including failed trials and patent challenges, pose risks to future performance.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Automatic translation: Originally published in undefined 04/08/2026, 17:30 GMT. Give feedback here.
POSITIVE CATALYSTS
Guidance raised for the second time in 2026: Novo raises its guidance for both adj. revenue and operating growth to 0% to -6% at CER (from -4% to -12%), driven by higher GLP-1 expectations. FCF guidance is raised to DKK 45-55 billion. The second raise in one year suggests that the bottom of the estimates may be near.
Wegovy pill delivers historic launch: Oral Wegovy surpassed 5 million prescriptions since launch with over 265,000 weekly prescriptions and "best-in-class" GLP-1 volume in the US. Now launched in UAE and UK, and EU-approved in July. Total Obesity care grew 16% at CER in Q2.
Strong cash flow and capital distribution: Free cash flow in H1 increased by 44% to DKK 55.3 billion, and DKK 41.2 billion was returned via dividend (35.3) and share repurchases (5.9). Net debt has decreased to DKK 86.5 billion from DKK 95.4 billion, providing financial flexibility.
NEGATIVE CATALYSTS / REDFLAG
Reported bottom line plummets: Reported EBIT fell 16% and net income 21% in Q2, impacted by a DKK 6.3 billion markdown on the pipeline (monlunabant alone DKK 4.0 billion). Gross margin fell to 78.2% from 82.7%, pressured by lower prices and ~DKK 3 billion in one-off costs for production capacity.
50% price decrease to hit in 2027: From January 1, 2027, the list price of Wegovy will decrease by ~50% and Ozempic by ~35% to USD 675 under the MFN agreement with the US. US Operations are already in contraction, and the structural price risk will pressure topline and margin going forward.
Pipeline disappointments are piling up: ZEUS Phase 3 with ziltivekimab failed its primary endpoint (possible new markdown in Q3), monlunabant has been terminated, and CagriSema missed non-inferiority on HbA1c vs. tirzepatide in REIMAGINE 4. At the same time, semaglutide patents are being challenged (Sandoz in UPC), and exclusivity is being lost in several markets.
Disclaimer: This is an HCA AI-generated research comment based solely on the company's published financial statements. The comment does not constitute investment advice and should not be the sole basis for investment decisions. Investing in shares involves a risk of loss. Seek professional advice. /HC Andersen Capital, 19:30, 04.08.2026
Login required
This content is only available for logged in users